Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Lu, Y; Xue, JX; Deng, T; Zhou, XJ; Yu, K; Deng, L; Huang, MJ; Yi, X; Liang, MZ; Wang, Y; Shen, HG; Tong, RZ; Wang, WB; Li, L; Song, J; Li, J; Su, XX; Ding, ZY; Gong, YL; Zhu, J; Wang, YS; Zou, BW; Zhang, Y; Li, YY; Zhou, L; Liu, YM; Yu, M; Wang, YQ; Zhang, XW; Yin, LM; Xia, XF; Zeng, Y; Zhou, Q; Ying, BW; Chen, C; Wei, YQ; Li, WM; Mok, T

Lu, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Thorac Oncol, Canc Ctr, Chengdu, Peoples R China.; Lu, Y (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.

NATURE MEDICINE, 2020; 26 (5): 732

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing of immune checkpoint genes could improve the efficacy of T cell therap......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索